7 Results for "

Alpha variant SARS-CoV-2

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Alpha variant SARS-CoV-2" in MCE Product Catalog:

Cat. No.: HY-149535
CAS No.: 2921711-74-0
Purity:  99.84%
Synonyms: WU-04
Target:  

SARS-CoV

Research Areas:  

Infection

Iscartrelvir (WU-04) is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .
loading...
    loading...
Cat. No.: HY-175029
CAS No.: 2892287-29-3
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
loading...
    loading...
Cat. No.: HY-159477
CAS No.: 2123489-12-1
Target:  

SARS-CoV

Research Areas:  

Infection Inflammation/Immunology

SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II .
loading...
    loading...
Cat. No.: HY-151265
CAS No.: 2719679-31-7
Target:  

SARS-CoV

Research Areas:  

Infection

MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .
loading...
    loading...
Cat. No.: HY-144120
Target:  

SARS-CoV

Research Areas:  

Infection

αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain
loading...
    loading...
Cat. No.: HY-173411
CAS No.: 3081926-49-7
Target:  

Glycosidase SARS-CoV

Research Areas:  

Infection Inflammation/Immunology

DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research .
loading...
    loading...
Cat. No.: HY-184171
CAS No.: 2883773-06-4
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

mCMX110 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 35 nM. mCMX110 inhibits SARS-CoV-2 infection. SARS-CoV-2 mCMX110 can be used for the research of SARS-CoV-2 infection .
loading...
    loading...